Capital Advisors Ltd. LLC Trims Holdings in DexCom, Inc. (NASDAQ:DXCM)

Capital Advisors Ltd. LLC cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 21.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 491 shares of the medical device company’s stock after selling 137 shares during the quarter. Capital Advisors Ltd. LLC’s holdings in DexCom were worth $38,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in DXCM. Versant Capital Management Inc acquired a new stake in DexCom during the 4th quarter worth approximately $25,000. Heck Capital Advisors LLC acquired a new stake in DexCom during the 4th quarter worth approximately $38,000. Midwest Capital Advisors LLC acquired a new stake in DexCom during the 4th quarter worth approximately $54,000. RPg Family Wealth Advisory LLC acquired a new stake in DexCom during the 3rd quarter worth approximately $57,000. Finally, Covestor Ltd lifted its holdings in DexCom by 53.7% during the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after buying an additional 335 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 38,083 shares of company stock valued at $3,309,794. 0.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on DXCM shares. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and raised their price objective for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Wells Fargo & Company raised their price objective on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $99.06.

DexCom Stock Up 2.2 %

Shares of DXCM stock opened at $90.75 on Tuesday. The stock has a market cap of $35.46 billion, a P/E ratio of 63.46, a price-to-earnings-growth ratio of 2.30 and a beta of 1.14. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The stock has a fifty day moving average price of $83.50 and a 200 day moving average price of $76.11. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.